Congrats Katherine! 🎉

We further unveil a novel therapeutic approach utilizing a first-in-class RSK inhibitor, PMD-026, that suppressed disease burden across syngeneic and PDX leukemia mouse models spanning the spectrum of driver and disease-modifying mutations.

Combining ATAC-Seq, CUT&Tag, RNA-seq, and CyTOF, we demonstrate that targeting of RSK1 suppresses NFκB activation and diminishes pro-inflammatory mediators including TNF associated with MPN disease severity and transformation.

Here we establish a comprehensive atlas across MPNs and secondary AML including RNA-sequencing of 158 primary samples encompassing CD34+ HPSCs and CD14+ monocytes. Supported by mass cytometry (CyTOF) profiling, we reveal aberrant PI3K/AKT/mTOR signaling and NFκB-mediated hyper-inflammation.

And check out my talk on Friday afternoon at the Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies where I will be highlighting work from superstar MSTP student Tim Kong!
ash.confex.com/ash/2024/web...

Come to Fan's oral presentation during the MPN session on Monday afternoon!
ash.confex.com/ash/2024/web...

Check out Molly's presentation during the poster walk on Saturday morning & at the evening poster session!
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...

#Publixsub FTW > Moffit or Coronado pizza #amirite

Very exciting Beth, congrats to your team and looking forward to these presentations!

Stay tuned for our companion manuscript which we anticipate sharing soon 😀. Finally, check out my talk on this work at the #ASH24 Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies!
@ash-hematology.bsky.social
ash.confex.com/ash/2024/web...

Also grateful to long-time collaborator Grant Challen as well as Sandi Dunn and Phoenix Molecular Designs for working closely with us on this effort. Excited to move this concept into the clinic in the near future!